In a dramatic development, Sanofi and Regeneron Pharmaceuticals can continue selling their cholesterol medicine while they fight an injunction that might force their drug off the market permanently, according to a federal appeals court ruling.
The court suspended a permanent injunction that was issued last month by a lower court, and would have prevented the companies from marketing Praluent, a new type of cholesterol treatment. The injunction was issued in response to a jury verdict last year that found the drug infringed on patents held by Amgen, which sells a rival medicine called Repatha.
About the Author Reprints
